Category Archives: Cell Therapy

31-01-2012 21:38 http://www.StemCellTreatment.org Jaime Chiriboga was an active adult and ended up in a motorcycle accident and left a quadriplegic. Before receiving stem cell treatment he could not move his limbs. After his stem cell therapy he was able to move his limbs and got back almost 100% sensitivity in his body! We are very happy with the results and even more important Jaime is happy with his results! Please look at our website for more information!

Originally posted here:
Stem Cell Treatment Paraplegic - Video

NEW YORK, Feb. 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Strategic Analysis of the European Stem Cell Research Tools Market

http://www.reportlinker.com/p0769016/Strategic-Analysis-of-the-European-Stem-Cell-Research-Tools-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

The primary objective of this study is to measure brand perceptions of tools and technologies currently at the forefront of stem cell research: bio-imaging and microscopy, cell biology tools, immunochemicals, molecular biology tools, and protein biochemistry tools. The study also looks into the usage pattern of these tools. An extensive end-user survey was conducted with 25 laboratories to assess the requirement and usage of tools. Insightful review of key industry drivers, restraints and challenges have been discussed. Leading market players and the prevailing competitive landscape for each of the segments have been discussed.

Table of ContentsExecutive Summary 10-19

Executive Summary 11-13

Market Engineering Measurements 14

Scope & Objective 15

Technologies Employed for Stem Cell Research 16

Stem Cell Research Protocol 17

CEO's Perspective 18

Exchange Rates 19

Market Overview 19

Market Overview - Definitions 20-24

Market Overview 25-26

Market Overview - Segmentation 27

European Stem Cell Research End User Trends 28

Stem Cell Research Workflow 29

Purpose of Research and Profile of Respondents 30

Stem Cells and Tools Usage Trends 31-33

Tools and Equipment Budget for Stem cell research Tools 34

Market Outlook 35

Market Age 36

Funding for Stem Cell Program 37-39

External Challenges: Drivers and Restraints 40

Industry Challenges 41-45

Drivers & Restraints 46

Key Market Participants 52

Product Line Analysis 59

Forecasts and Trends -Total Stem Cell Research Tools Market 70

Forecast Assumptions 72

Revenue Forecasts 73-74

Bio Imaging Tools In Vivo and In Vitro Segment Breakdown 75

Revenue Forecasts 77-78

Market Share Analysis 79

Cell Biology, Protein Biochemistry, and Immunochemical Tools Segment Breakdown 80

Revenue Forecasts 82-83

Market Share Analysis 84

Molecular Biology Tools Segment Breakdown 85

Revenue Forecasts 87-88

Market Share Analysis 89

Demand Analysis 90

Bioimaging Tools In Vivo and In Vitro 92

Cell Biology Tools 93

Demand Analysis Molecular Biology Tools 94

Protein Biochemistry Tools 95

Immunochemical Tools 96

European Stem Cell Research Centers 97-99

SWOT Analysis 101-102

Strategic Recommendations and Conclusions 103-106

The Last Word 107

Appendix 110

List of Figures

Total Stem Cell Research Tools Market: Market Overview, Europe, 2010 25Total Stem Cell Research Tools Market: Tools Usage Trends, Europe, 2010 32-33Total Stem Cell Research Tools Market: Market Outlook, Europe, 2010 35Total Stem Cell Research Tools Market: R&D Programs Funded, Europe, 2006–2013 37Total Stem Cell Research Tools Market: Bioimaging Tools In Vivo and In Vitro End User Analysis, Europe, 2010 92Total Stem Cell Research Tools Market: Cell Biology Tools End User Analysis, Europe, 2010 93Total Stem Cell Research Tools Market: Molecular Biology Tools End User Analysis, Europe, 2010 94Total Stem Cell Research Tools Market: Protein Biochemistry Tools End User Analysis, Europe, 2010 95Total Stem Cell Research Tools Market: Immunochemical Tools End User Analysis, Europe, 2010 96

List of Charts

Percent Revenue Breakdown Total Stem Cell Research Tools Market: Europe, 2010 27

Percent Revenue Breakdown Total Stem Cell Research Tools Market: Europe, 2017 27

Total Stem Cell Research Tools Market: Purpose of Research and Profile of Respondents, Europe, 2010 30

Total Stem Cell Research Tools Market: General and Primary Focus on Stem Cell Research, Europe, 2010 31

Total Stem Cell Research Tools Market: Lab Budgets, Europe, 2010 34

Total Stem Cell Research Tools Market: Lab Budget Estimations, Europe, 2011 34

Total Stem Cell Research Tools Market: Segment Life Cycle Analysis, Europe, 2010 36

Total Stem Cell Research Tools Market: Industry Challenges, Europe, 2011–2017 41

Total Stem Cell Research Tools Market: Drivers and Restraints, Europe, 2010 46

Total Stem Cell Research Tools Market: Product Line Analysis, Europe, 2010 59-67

Market Overview Total Stem Cell Research Tools: Europe, 2010 71

Total Stem Cell Research Tools: Revenue Forecast, Europe, 2010–2017 73

Market Overview Bioimaging In Vivo and In Vitro Market: Europe, 2010 76

Bioimaging Tools In Vivo and In Vitro Market: Revenue Forecasts, Europe, 2010–2017 77

Bioimaging In Vivo and In Vitro Market: Market Share Analysis, Europe, 2010 79

Market Overview Cell Biology, Protein Biochemistry, and Immunochemical Tools Market: Europe, 2010 81

Cell biology, Protein Biochemistry, and Immunochemical Tools Market Revenue Forecasts, Europe, 2010–2017 82

Cell Biology, Protein Biochemistry, and Molecular Biology Tools Market: Market Share Analysis, Europe, 2010 84

Market Overview Molecular Biology Tools Market: Europe, 2010 86

Molecular Biology Tools Market: Revenue Forecasts, Europe, 2010–2017 87

Molecular Biology Tools Market: Market Share Analysis, Europe, 2010 89

Total Stem Cell Research Tools Market: Research Centers and Universities, Europe, 2010 98-100

Total Stem Cell Research Tools Market: SWOT Analysis, Europe, 2010 102

To order this report:Biological Therapy Industry: Strategic Analysis of the European Stem Cell Research Tools Market

More  

Market Research Report

Check our  

Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

See original here:
Strategic Analysis of the European Stem Cell Research Tools Market

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI.OB - News), a leading developer of adult stem cell technologies and therapeutics, announced today that the prestigious Experimental Neurology Journal, published an article indicating that preclinical studies using cells that underwent treatment with Brainstorm’s NurOwn™ technology show promise in an animal model of Huntington’s disease. The article was published by leading scientists including Professor Melamed and Professor Offen of the Tel Aviv University.

In these studies, bone marrow derived mesenchymal stem cells secreting neurotrophic factors (MSC-NTF), from patients with Huntington’s disease, were transplanted into the animal model of this disease and showed therapeutic improvement.

“The findings from this study demonstrate that stem cells derived from patients with a neurodegenerative disease, which are processed using BrainStorm’s NurOwn™ technology, may alleviate neurotoxic signs, in a similar way to cells derived from healthy donors. This is an important development for the company, as it confirms that autologous transplantation may be beneficial for such additional therapeutic indications,” said Dr. Adrian Harel, BrainStorm’s CEO.

"These findings provide support once again that BrainStorm’s MSC-NTF secreting cells have the potential to become a platform that in the future will provide treatment for various neuro-degenerative diseases," says Chaim Lebovits, President of BrainStorm. "This study follows previously published pre-clinical studies that demonstrated improvement in animal models of neurodegenerative diseases such as Parkinson’s, Multiple Sclerosis (MS) and neural damage such as optic nerve transection and sciatic nerve injury. Therefore, BrainStorm will consider focusing on a new indication in the near future, in addition to the ongoing Clinical Trials in ALS.”

BrainStrom is currently conducting a Phase I/II Human Clinical Trial for Amyotrophic Lateral Sclerosis (ALS) also known as Lou Gehrig’s disease at the Hadassah Medical center. Initial results from the clinical trial (which is designed mainly to test the safety of the treatment), that were announced last week, have shown that the Brainstorm’s NurOwn™ therapy is safe and does not show any significant treatment-related adverse events and have also shown certain signs of beneficial clinical effects.

To read the Article entitled ‘Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: A potential therapy for Huntington's disease’ by Sadan et al. please go to:

http://www.sciencedirect.com/science/article/pii/S0014488612000295

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotech company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The company, through its wholly owned subsidiary Brainstorm Cell Therapeutics Ltd., holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The technology is currently in a Phase I/II clinical trials for ALS in Israel.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements, including, inter alia, regarding safety and efficacy in its human clinical trials and thereafter; the Company's ability to progress any product candidates in pre-clinical or clinical trials; the scope, rate and progress of its pre-clinical trials and other research and development activities; the scope, rate and progress of clinical trials we commence; clinical trial results; safety and efficacy of the product even if the data from pre-clinical or clinical trials is positive; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of our proposed product candidates; dependence on the efforts of third parties; failure by us to secure and maintain relationships with collaborators; dependence on intellectual property; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility, and risks that we may lack the financial resources and access to capital to fund our operations. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect its technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.

View post:
Experimental Neurology Journal: BrainStorm's NurOwn™ Stem Cell Technology Shows Promise for Treating Huntington's ...

31-01-2012 15:24 MDA Vice President of Research Sanjay Bidichandani explains the promising research being done in neuromuscular disease research using adult stem cells.

Read more from the original source:
Stem Cell Therapy in Neuromuscular Disease Research - Video

ScienceDaily (Jan. 30, 2012) — Mouse skin cells can be converted directly into cells that become the three main parts of the nervous system, according to researchers at the Stanford University School of Medicine. The finding is an extension of a previous study by the same group showing that mouse and human skin cells can be directly converted into functional neurons.

The multiple successes of the direct conversion method could refute the idea that pluripotency (a term that describes the ability of stem cells to become nearly any cell in the body) is necessary for a cell to transform from one cell type to another. Together, the results raise the possibility that embryonic stem cell research and another technique called "induced pluripotency" could be supplanted by a more direct way of generating specific types of cells for therapy or research.

This new study, published online Jan. 30 in the Proceedings of the National Academy of Sciences, is a substantial advance over the previous paper in that it transforms the skin cells into neural precursor cells, as opposed to neurons. While neural precursor cells can differentiate into neurons, they can also become the two other main cell types in the nervous system: astrocytes and oligodendrocytes. In addition to their greater versatility, the newly derived neural precursor cells offer another advantage over neurons because they can be cultivated to large numbers in the laboratory -- a feature critical for their long-term usefulness in transplantation or drug screening.

In the study, the switch from skin to neural precursor cells occurred with high efficiency over a period of about three weeks after the addition of just three transcription factors. (In the previous study, a different combination of three transcription factors was used to generate mature neurons.) The finding implies that it may one day be possible to generate a variety of neural-system cells for transplantation that would perfectly match a human patient.

"We are thrilled about the prospects for potential medical use of these cells," said Marius Wernig, MD, assistant professor of pathology and a member of Stanford's Institute for Stem Cell Biology and Regenerative Medicine. "We've shown the cells can integrate into a mouse brain and produce a missing protein important for the conduction of electrical signal by the neurons. This is important because the mouse model we used mimics that of a human genetic brain disease. However, more work needs to be done to generate similar cells from human skin cells and assess their safety and efficacy."

Wernig is the senior author of the research. Graduate student Ernesto Lujan is the first author.

While much research has been devoted to harnessing the pluripotency of embryonic stem cells, taking those cells from an embryo and then implanting them in a patient could prove difficult because they would not match genetically. An alternative technique involves a concept called induced pluripotency, first described in 2006. In this approach, transcription factors are added to specialized cells like those found in skin to first drive them back along the developmental timeline to an undifferentiated stem-cell-like state. These "iPS cells" are then grown under a variety of conditions to induce them to re-specialize into many different cell types.

Scientists had thought that it was necessary for a cell to first enter an induced pluripotent state or for researchers to start with an embryonic stem cell, which is pluripotent by nature, before it could go on to become a new cell type. However, research from Wernig's laboratory in early 2010 showed that it was possible to directly convert one "adult" cell type to another with the application of specialized transcription factors, a process known as transdifferentiation.

Wernig and his colleagues first converted skin cells from an adult mouse to functional neurons (which they termed induced neuronal, or iN, cells), and then replicated the feat with human cells. In 2011 they showed that they could also directly convert liver cells into iN cells.

"Dr. Wernig's demonstration that fibroblasts can be converted into functional nerve cells opens the door to consider new ways to regenerate damaged neurons using cells surrounding the area of injury," said pediatric cardiologist Deepak Srivastava, MD, who was not involved in these studies. "It also suggests that we may be able to transdifferentiate cells into other cell types." Srivastava is the director of cardiovascular research at the Gladstone Institutes at the University of California-San Francisco. In 2010, Srivastava transdifferentiated mouse heart fibroblasts into beating heart muscle cells.

"Direct conversion has a number of advantages," said Lujan. "It occurs with relatively high efficiency and it generates a fairly homogenous population of cells. In contrast, cells derived from iPS cells must be carefully screened to eliminate any remaining pluripotent cells or cells that can differentiate into different lineages." Pluripotent cells can cause cancers when transplanted into animals or humans.

The lab's previous success converting skin cells into neurons spurred Wernig and Lujan to see if they could also generate the more-versatile neural precursor cells, or NPCs. To do so, they infected embryonic mouse skin cells -- a commonly used laboratory cell line -- with a virus encoding 11 transcription factors known to be expressed at high levels in NPCs. A little more than three weeks later, they saw that about 10 percent of the cells had begun to look and act like NPCs.

Repeated experiments allowed them to winnow the original panel of 11 transcription factors to just three: Brn2, Sox2 and FoxG1. (In contrast, the conversion of skin cells directly to functional neurons requires the transcription factors Brn2, Ascl1 and Myt1l.) Skin cells expressing these three transcription factors became neural precursor cells that were able to differentiate into not just neurons and astrocytes, but also oligodendrocytes, which make the myelin that insulates nerve fibers and allows them to transmit signals. The scientists dubbed the newly converted population "induced neural precursor cells," or iNPCs.

In addition to confirming that the astrocytes, neurons and oligodendrocytes were expressing the appropriate genes and that they resembled their naturally derived peers in both shape and function when grown in the laboratory, the researchers wanted to know how the iNPCs would react when transplanted into an animal. They injected them into the brains of newborn laboratory mice bred to lack the ability to myelinate neurons. After 10 weeks, Lujan found that the cells had differentiated into oligodendroytes and had begun to coat the animals' neurons with myelin.

"Not only do these cells appear functional in the laboratory, they also seem to be able to integrate appropriately in an in vivo animal model," said Lujan.

The scientists are now working to replicate the work with skin cells from adult mice and humans, but Lujan emphasized that much more research is needed before any human transplantation experiments could be conducted. In the meantime, however, the ability to quickly and efficiently generate neural precursor cells that can be grown in the laboratory to mass quantities and maintained over time will be valuable in disease and drug-targeting studies.

"In addition to direct therapeutic application, these cells may be very useful to study human diseases in a laboratory dish or even following transplantation into a developing rodent brain," said Wernig.

In addition to Wernig and Lujan, other Stanford researchers involved in the study include postdoctoral scholars Soham Chanda, PhD, and Henrik Ahlenius, PhD; and professor of molecular and cellular physiology Thomas Sudhof, MD.

The research was supported by the California Institute for Regenerative Medicine, the New York Stem Cell Foundation, the Ellison Medical Foundation, the Stinehart-Reed Foundation and the National Institutes of Health.

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Stanford University Medical Center. The original article was written by Krista Conger.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

E. Lujan, S. Chanda, H. Ahlenius, T. C. Sudhof, M. Wernig. Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. Proceedings of the National Academy of Sciences, 2012; DOI: 10.1073/pnas.1121003109

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Read more from the original source:
Skin cells turned into neural precusors, bypassing stem-cell stage